Triomics Secures $22M in Series B Funding to Revolutionize Cancer Treatment with AI
TL;DR
- Triomics raised $22 million in Series B funding to expand its oncology-specific AI platform for cancer centers.
- The round was led by Battery Ventures, with support from existing backers including Nexus Venture Partners, Lightspeed, and Y Combinator.
- The company says the capital will help automate high-friction oncology workflows such as clinical trial matching, appointment prep, and tumor registry reporting.
A fresh funding boost for oncology AI
Triomics has raised $22 million in Series B financing to scale its artificial intelligence platform for cancer care teams, according to a report published on May 27, 2026. The company’s software is designed to help oncologists and administrative staff handle data-heavy, time-consuming tasks more efficiently.
Battery Ventures led the round, while Nexus Venture Partners, Lightspeed, Y Combinator, and other returning investors also participated.
What Triomics is building
Founded in 2021, Triomics focuses on the messy, unstructured data that dominates oncology workflows, including lengthy patient records and clinical documentation. Its platform uses an oncology-focused AI system to summarize records, surface relevant information, and support use cases such as trial matching and workflow automation.
The company’s technology is also positioned around its OncoLLM model, which has been described as a large language model tailored to oncology-specific tasks.
Why cancer centers care
Cancer care generates enormous volumes of complex data, and much of it is still handled manually. Triomics says its AI tools can reduce the burden of tasks such as preparing for appointments, matching patients to clinical trials, and submitting tumor reports to government registries, which is a legal requirement for cancer centers.
That matters because trial matching and documentation workflows can take clinicians and staff away from direct patient care. Automating those steps could improve operational efficiency and help providers move faster from diagnosis to treatment planning.
Where the new capital goes
The new funding is expected to help Triomics expand its AI solutions and deepen adoption across oncology centers. In practical terms, that likely means more product development, broader deployment, and further refinement of the company’s workflow automation tools for cancer providers.
Triomics previously raised $15 million in Series A funding in mid-2024, showing that investor interest in its oncology-focused approach has been building over time.
A broader trend in healthcare AI
Triomics’ latest raise fits into a wider surge of investment in healthcare AI, especially tools that aim to cut administrative friction rather than replace clinical judgment. In oncology, where records are complex and care pathways are highly specialized, AI companies are increasingly targeting tasks that are both repetitive and critical to care coordination.
The company is betting that cancer centers will adopt AI fastest when it directly saves time, improves documentation quality, and helps identify more patients for potentially relevant clinical trials.
What to watch next
The key question now is whether Triomics can translate investor enthusiasm into measurable clinical and operational gains. If its tools can reliably reduce manual work while improving patient matching and reporting, the company could become a notable player in oncology operations software.
For cancer centers under pressure to do more with limited staff, that combination of automation and specialty-specific intelligence may prove especially compelling.
Get All The Latest Updates Delivered Straight To Your Inbox For Free!